11 regenerative nodules and 98 HCCs were documented. An additional 34 nodules of HCC (24% of total nodules) were identified by histology only and not seen on pretransplant imaging. These nodules ranged in size from <0.1 cm to 4.0 cm. 64% of these nodules measured ≤1.0 cm. Larger nodules (3-4cm) were comprised of many small tumor nodules growing in a military-type pattern. Treatment effect of 73 nodules was correlated with the LI-RADS suspicion (low, moderate, or high) for residual HCC. Conclusions: Periportal CK7 has higher sensitivity than copper stain in demonstrating chronic cholestasis, while copper stain is more specific. Combined use of both stains increases the sensitivity for diagnosis for PSC, and increases specificity for PBC/PSC vs. AIH diagnosis. Positive result with both stains strongly points to biliary disease even in high stage setting. Combined use of copper and CK7 stains is recommended in liver biopsies for all cases of suspected chronic biliary disease.
Aldoketoreductase Family 1B10 (AKR1B10) Is a Sensitive Biomarker to Identify Well-Differentiated Hepatocellular Carcinoma
Andrew Bandy, Xiaoming You, Haonan Li, Jie Liao, Sambasiva Rao, Xiaoqi Lin, Guang-Yu Yang. Northwestern University, Chicago, IL. Background: Well-differentiated hepatocellular carcinoma (WD-HCC) is the most common primary malignant hepatic neoplasm which is extremely challenging for a pathologic diagnosis, particularly for needle core biopsy specimens. Although there are many immunohistochemical and special stains currently employed to aid in distinguishing this malignant disease from metastatic diseases and benign lesions in the liver, each has varying usefulness depending on the differential diagnosis. One recently described protein, AKR1B10, may aid in distinguishing HCC from its benign mimickers, as AKR1B10 has been shown to be upregulated in many HCCs. Design: A total of 63 cases of HCC were retrieved from our institution, including 23 core needle biopsies and 40 liver explants. Immunohistochemistry for AKR1B10 was performed for all cases with proper positive and negative controls. AKR1B10 staining was evaluated based on intensity of cytoplasmic staining of tumor cells (negative, weak, moderate and strong) and the proportion of overall tumor that stained (<10%, 10-50% and >50%). Results: In this cohort, 49/63 (78%) of the WD-HCCs showed moderate or higher staining intensity with AKR1B10 in >50% of tumor cells, including 37/63 cases (59%) which displayed strong staining (Fig. 1a) . When considering the utility of AKR1B10 in needle core biopsies, 23/23 cases exhibited strong staining, and 20/23 (87%) exhibited strong staining in >50% of tumor cells (Fig. 1b) . The morphologically normal liver parenchyma remote from HCC showed negative AKR1B10 staining. Focal and weak positive staining was observed in benign hepatocytes adjacent to HCC (Fig. 1c) . Conclusions: Our study demonstrated that AKR1B10 is upregulated in WD-HCCs. AKR1B10 is a sensitive marker for distinguishing benign hepatocytes from WD-HCC, and this is particularly true in limited sample specimens such as needle core biopsies where architecture cannot fully be assessed. 
Conclusions:
Although not evident in the early OLT period, biliary alterations were more common in the DCD group 6 m after OLT raising concern for vulnerability to biliary injury. There were more features of parenchymal ischemia in the early OLT period in DCD patients indicating poor graft perfusion. However, 1 year graft survival between the two groups was similar suggesting graft recovery.
Prognosis of HER2 Expression in Cholangiocarcinoma
Antonio Campos, Maria O Begnami, Viviane T Fernandes, Milton JDBE Silva, Maria Begnami. A C Camargo Cancer Center, Sao Paulo, SP, Brazil. Background: The tumors of the biliary tract can arise anywhere in the biliary tree or less frequent from transdifferentiation of hepatocytes. This tumor is lethal with heterogeneous behavior and complex molecular biology representing 0.6-1% of tumors among adults. Several studies highlight the role of HER2 in cholangiocarcinoma pathogenesis and its expression seems to be present from the onset of carcinogenesis.
The prognostic value of HER2 in this population is a matter of debate and the pattern of expression of HER2 is heterogeneous as in gastric cancer. The aim of this study was to evaluate the prognostic role of HER2 by immunohistochemistry using the methodology validated for gastric cancer in a western population with cholangiocarcinoma. Design: We have done a retrospective review of clinical and pathological features on electronic medical charts of patients with cholangiocarcinoma and HER2 immunohistochemistry testing using gastric cancer methodology. Statistical associations between individual variables and OS were analyzed using the log-rank test. Individual variables with a P value less than 0.2 in univariate analysis were tested in a multivariate analysis, using the Cox proportional hazards model. Results: Among the 46 patients selected, 38 were evaluated for the expression of HER2. The expression of HER2 (2 or 3+) was found in 30% of the cases. In multivariate analysis, the expression of HER2 (2 or 3 +) was a independent prognostic factor of overall survival with a HR for mortality of 3.08 (1.23 to 7.28) with P=0.01. This prognostic factor was observed in both localized and metastatic disease.
Conclusions: HER2 immunohistochemistry using gastric cancer methodology was positive (2 or 3+) in 30% of our western population of cholangiocarcinoma and was an independent prognostic factor. Prospective studies are needed to validate the best method for assessing HER2 expression and if there is a predictive value for using anti-HER therapy in this selected population.
Combination of Astrocyte Elevated Gene 1 and Glypican 3 Immunochemistry Improves Diagnostic Accuracy of Hepatocellular Carcinoma
Wenqing Cao, Benedict Maliakkal, Mark Orloff, Meenal Sharma. New York University Langone Medical Center, New York, NY; University of Rochester Medical Center, Rochester, NY. Background: Expression of Glypican 3 (GPC-3) is often negative or patchy/focal positive in well to moderately differentiated hepatocellular carcinomas (HCC), although GPC-3 is considered as a specific marker in differentiating poorly differentiated HCC from benign hepatocellular proliferation or metastatic carcinoma. Additional markers are needed to assist diagnosing early hepatocellular neoplasms. Recently, astrocyte elevated gene 1 (AEG-1) was identified as a new diagnostic marker for HCC. We studied the diagnostic values of AEG1, GPC-3 and combination of both markers in HCC. Design: AEG-1 and GPC-3 were studied by immunohistochemistry in a total of 46 resected tumors from 37 HCC patients. They included 37 HCCs (9 well, 20 moderately and 8 poorly differentiated) with adjacent nonneoplastic liver tissues (NON), and 9 dysplastic nodules (DN). The staining of AEG-1 and GPC-3 were evaluated and assigned to one of the following categories: negative, weak staining or ≤5% of tumor cells with moderate to strong staining; positive, moderate or strong staining seen in >5% but ≤50% (focal), or diffuse, in >50% (diffuse) of the tumor cells. Fisher exact analysis was applied to compare the proportions between the groups. Results: Positive AEG-1 and GPC-3 staining was seen in 91.9% (34/37) and 56.8% (21/37) of HCCs respectively. Diffuse AEG-1 staining was seen in 89% of HCCs, 5% of DNs and 11% of NONs. Diffuse positive GPC-3 was found in 41% of HCCs, 5% of DNs and 0% NONs. 14 (4 well, 6 moderately, and 4 poorly differentiated) GPC-3 negative and 5 (1 well and 4 moderately differentiated) GPC-3 focal positive HCCs showed diffuse positive staining of AEG-1. Two AEG-1 negative HCCs showed focal positive GPC-3 staining. One moderately differentiated HCC was negative for both AEG-1 and GPC-3. The sensitivity and specificity for diffuse AEG-1 staining was 89% and 95% respectively. The sensitivity and specificity for diffuse GPC-3 staining was 41% and 100% respectively. The sensitivity and specificity was 94% and 95% for the combination of diffuse AEG-1 and GPC-3 staining.
Conclusions: AEG-1 shows better sensitivity than GPC-3, whereas GPC-3 appears more specific for HCC. AEG-1 combined with GPC-3 may be a promising approach to discriminate HCC from benign hepatocellular proliferation. Vishal Chandan, Sejal S Shah, Roger Moreira, Tsung-Teh Wu, Michael Torbenson. Mayo Clinic, Rochester, MN. Background: The arginase-1 immunostain is an excellent marker of hepatocellular differentiation and is a sensitive and specific marker for hepatocellular carcinoma (HCC). However, we have anecdotally encountered occasional well-differentiated HCC (WDHCC) that were negative for arginase-1, including cases submitted for surgical consultation. The aim of this study was to assess the prevalence of arginase-1 positivity in WDHCC on needle biopsy material. Design: 68 consecutive cases of WDHCCs diagnosed on needle biopsies (age range 34-93 years; 52 males and 16 females) were retrieved from our pathology files (including consult cases) between 2012-2015. The diagnosis of WDHCC was based on typical morphological findings on hematoxylin and eosin stain with loss of normal reticulin staining pattern on the reticulin stain. Arginase-1 stain was performed on all cases. Additional stains including hepar-1, glypican-3, albumin ISH were also performed as needed. For each stain, any expression within the tumor was considered positive. Results: 7 of 68 (10%) WDHCCs were completely negative for arginase-1 (age range 55-84 years; 7 males). 6 of these 7 cases included the background non-neoplastic liver parenchyma within the biopsy and this non-neoplastic liver parenchyma was positive for arginase-1 in all 6 cases (100%). All these 7 cases (100%) were positive for hepar-1. Glypican-3 was positive in 4/7 (57%) cases. Albumin ISH was also performed on 2/7 cases and both (100%) were positive. Results: ERG was positive in all 10 (100%) epithelioid hemangioendotheliomas (2, 2+; 1, 3+; 7, 4+) and all 13 (100%) angiosarcomas (1, 1+; 2, 3+; 10, 4+). CK7 was positive in 6/10 (60%) epithelioid hemangioendotheliomas (3, 1+; 1, 2+; 1, 3+; 1, 4+) and 1/13 (8%) angiosarcoma (epithelioid type, 2+). Keratin OSCAR was positive in 6/10 (60%) epithelioid hemangioendotheliomas (5, 1+; 1, 2+) and 4/13 (31%) angiosarcomas (3 epithelioid and 1 spindle type, 2, 1+; 1, 2+; 1, 4+). Keratin AE1/AE3 was positive in 6/10 (60%) epithelioid hemangioendotheliomas (3, 1+; 3; 2+) and 4/13 (31%) angiosarcomas (3 epithelioid and 1 spindle type, 2, 1+; 1, 2+; 1, 4+). Overall, 7 of 10 (70%) epithelioid hemangioendotheliomas were positive for at least one keratin marker and out of these 5 (50%) were positive for all 3 keratins (AE1/AE3, OSCAR and CK7) while 1 (10%) was positive for 2 keratins (OSCAR and AE1/AE3) and another 1 (10%) was positive for only CK7. 4 of 13 (31%) of angiosarcomas were positive for both keratins OSCAR and AE1/AE3, while 1 of these 4 cases was also positive for CK7. Conclusions: Aberrant keratin expression is common in primary hepatic epithelioid hemangioendotheliomas (7 of 10 cases, 70%) and angiosarcomas (4 of 13 cases, 31%). Awareness of this potential diagnostic pitfall is important for correct diagnosis of these primary hepatic malignant vascular tumors and for avoidance of misdiagnosis as carcinomas. Copper deposition was evaluated as negative (no copper), focal (F=1 or 2 foci of copper in the lesion), patchy (P=more than 2 foci but less than half of the lesion) and diffuse (D=more than half of the lesion). When copper was detected, the intensity of deposition was scored as 1+ (isolated cells containing small sparse granules, not seen at low power), 2+ (moderate to numerous copper granules, seen at low power, mainly around the areas of fibrosis/pseudo portal tracts), 3+ (widespread and heavy deposition of granules throughout the lesion n=34; 2006-2015) , the overall rate of PASD+ globules was 44% (15/34). Average BMI at time of transplant was 27.4 kg/m 2 . Cases without globules had an average BMI of 26.9 kg/m 2 , while those with globules had an average BMI of 31.5 kg/m 2 (p=0.003). The higher BMI with globules was true for both NASH (ave BMI 33.3, p=0.0028) and non-NASH (BMI 30.7, p=0.007). There was no significant difference in other clinical parameters, including ethnicity or gender. Serum A1AT levels were available in <5% of cases. Conclusions: PASD+ globules occurred significantly more often in explants for NASH than in other diseases. Also, the BMI in pts with PASD+ globules was statistically increased in both NASH and non-NASH. Interestingly, a BMI of 30 kg/m 2 , the clinical definition of obesity, significantly predicted the presence of PASD+ globules (p=0.0002). This suggests that A1AT globules in explants are not simply a nonspecific effect of cirrhosis, but may be related to obesity. It may further indicate that NASH and A1AT deficiency have a synergistic effect on cirrhosis, or that obesity affects A1AT secretion. The lack of clinical follow-up to correlate with explant findings emphasizes the need to evaluate for A1AT in all liver transplant candidates.
10% of Well Differentiated Hepatocellular Carcinomas Are Negative for Arginase-1 on Needle Biopsies: An Important Diagnostic Pitfall

Extramedullary Hematopoiesis Presenting as Focal Lesions in Liver: A Pathological and Radiological Study
Gregory Cheeney, Matthew Yeh. University of Washington, Seattle, WA. Background: Extramedullary hematopoiesis (EMH) is the presence of hematopoietic stem cells outside of the bone marrow. EMH is a common incidental finding in the organs of the reticuloendothelial system, including the liver and spleen, in patients with myelodysplastic disorders. Diffuse EMH of the liver and spleen may present as hepatosplenomegaly. Far more rare is EMH presenting as a focal intrahepatic lesion, with only 14 case reports within the literature. The purpose of this study is to characterize the pathologic, radiographic, and clinical features of intrahepatic EMH presenting as focal hepatic lesions. Design: All liver biopsy and explant as well as autopsy cases containing the term "Extramedullary hematopoiesis" dating back 15 years at our institutewere reviewed. The cases were cross-referenced for any cross sectional imaging performed within 1 year of pathology results. Of the 825 cases meeting the initial search parameters, 12 cases had focal hepatic lesion on pre-procedural imaging. This was furthered narrowed to 9 as 2 had other pathology and one was unclear if the biopsy was truly from the focal lesion. Results: 9 cases (4:5 M:F, 54.7 (+15) years old) (7 biopsies and 2 explants) had EMH present in focal liver lesions identified on CT or MRI (2 MR and 7 CT, all with at least single phase enhancement). Of the 9 cases, 7 had multiple lesions and 2 had a single focus. The 2 cases identified on liver MR imaging had both arterial enhancement and washout on delayed imaging with multiple lesions all less than a centimeter. The 7 cases identified on CT had 5 with low attenuation and 2 with hyperattenuation on venous phase imaging, and all with arterial phase enhancement when performed. About half the patients had hematological disorders, with the remaining cases from patients from screening cirrhosis protocols and metastatic disease work up. Most cases of prospectively identified hepatic EMH were classified as indeterminate, an equivalent grade of Li-Rads 3, and several were suggestive of a hemangioma. Conclusions: This is the largest report of hepatic EMH presenting as focal lesions. Focal EMH generally presents as multiple ill-defined arterially enhancing subcentimeter lesions on MRI and CT with most lesions having hypoattenuation on venous phase imaging. Focal hepatic EMH identified in CT and MRI, although rare, should be a consideration in indeterminate liver lesions. In addition, given the high frequency of patients with hematological disorders, these need to be considered clinically when EMH presents as focal lesions on imaging. Background: Reticulin loss is a diagnostic criterion in differentiating hepatocellular carcinoma (HCC) from several benign hepatocellular lesions. Reticulin loss can be observed in fat-containing areas of benign hepatocellular lesions, however. Anecdotally, we noted several cases of telangiectatic/inflammatory hepatocellular adenoma (TA) with focal reticulin loss in areas that did not contain fat, including a case that had been diagnosed as HCC. Design: A case-finding search from 2011 to 2015 yielded 21 specimens from 15 patients (1 male, 14 females from 30-51 years old; mean: 39.8) of TA for which adequate tissue remained in the paraffin block. These were comprised of 5 biopsies and 16 resections and included 2 biopsies with subsequent resection specimens. The cases were rereviewed to confirm the diagnosis of TA and representative blocks were chosen to assess reticulin pattern. The amount of fat was noted, but reticulin pattern was only assessed in the areas devoid of fat. Results: Three patterns of reticulin alterations were identified. Twenty (95%) specimens showed regenerative hyperplasia (RH)-like staining in the periportal areas whereby the hepatocellular plate thickness was increased to 3-4 cells, but there was no HCC-type reticulin loss. Twenty (95%) of specimens showed a sinusoidal-obstruction syndrome (SOS)-like pattern in the telangiectatic areas in which the sinusoidal spaces were filled with fine reticulin fibers. Finally, a third subset (24%; 2 biopsies; 3 resections) showed reticulin loss similar to that found in HCC. Conclusions: Reticulin loss in fat-containing benign hepatocellular lesions is a wellrecognized pitfall for misdiagnosis of HCC. HCC-type reticulin loss also occurs in a minority of TAs and should not be the sole determinant of malignancy in an otherwise typical TA, especially on needle core biopsies. Further, we found that RH-type reticulin staining adjacent to portal-like structures and SOS-type staining in areas of telangiectasia are quite common in TA, and these features may aid in the diagnosis of TA. Although it is generally accepted that donor livers with < 30% large droplet macrovesicular steatosis, and/or small droplet macrovesicular steatosis (irrespective of percentage) are safe to use (with > 60% "steatosis" reported as unsafe), this consensus is based on variable definitions of macrovesicular steatosis subtypes, sometimes including "microvesicular steatosis" in the same category as "small droplet macrovesicular steatosis," and/or without a reproducible scoring system or consistent clinical variables. Design: 75 deceased donor liver biopsies from allografts transplanted at UCSF Medical Center between 2009 and 2015 were analyzed to determine if large and/or small droplet macrovesicular steatosis is a risk factor for poor outcome. Frozen and/or permanent section specimens were reviewed to determine the degree and type of steatosis. Large droplet macrovesicular steatosis was defined as a fat droplet occupying greater than one-half of an individual hepatocyte, with nuclear displacement, and scored as the percentage of parenchyma replaced by large droplets on 4x magnification. Small droplet macrovesicular steatosis was defined as one to several fat droplets, each occupying less than one-half of an individual hepatocyte, and scored as the percentage of hepatocytes containing small droplets on 10x magnification. Electronic medical records were reviewed to determine histologic and clinical outcomes.
Results: There is a significant increased risk for biliary obstruction (hazard ratio (HR) = 6.0, p = 0.0398) in the donor livers with > 30% small droplet macrovesicular steatosis. However, there was no significant difference in the rates of acute/chronic rejection (HR = 1.2, p = 0.6376), vascular obstruction (HR = 2.3, p = 0.2834), recurrent disease (HR = 1.5, p = 0.3886), or patient survival (HR = 2.3, p = 0.2834) between the two groups. Similarly, 30-60% large droplet macrovesicular steatosis was not a risk factor for poor outcomes (p = 0.1362-0.9947, n = 7). Conclusions: Distinct assessment of small and large droplet macrovesicular steatosis is important in donor liver biopsy evaluation as > 30% small droplet macrovesicular steatosis was associated with increased risk for post-transplant biliary obstruction. Todd DeJulio, Xiaoming You, Haonan Li, Jie Liao, Sambasiva Rao, Nike Beaubier, Guang-Yu Yang. Northwestern University, Chicago, IL. Background: Recent publications have asserted that subclassification of intrahepatic cholangiocarcinoma is possible based on morphologic, clinical and molecular findings. The two main types of intrahepatic cholangiocarcinoma are cholangiolar and bile duct types. Morphologically, the bile duct type (Fig. 1a) shows infiltrating, small ducts with low cuboidal epithelium, while the cholangiolar type ( Fig. 1c) shows a large glandular pattern with columnar epithelium. Whether there are different histogenesis and molecular phenotypes in these two types of tumors is not known. Generally, the bile duct type of cholangiocarcinoma shows morphologic findings similar to those seen in a bile duct adenoma. Since bile duct adenoma displays foregut histogenic origin and MUC6 serves as a foregut biomarker, in this study, MUC6 expression is evaluated immunohistochemically on intrahepatic cholangiocarcinomas and bile duct adenomas. Design: A total of 25 intrahepatic cholangiocarcinomas and 14 bile duct adenomas were assessed. Formalin-fixed paraffin-embedded sections were labeled with a monoclonal antibody to MUC6 with appropriate positive and negative controls. Tumors were scored as positive if dense cytoplasmic staining was seen. Results: 14 of 14 (100%) of the bile duct adenomas and 11 of 25 (44%) of the intrahepatic cholangiocarcinomas showed strong positive staining for MUC6. All 11 of the MUC6-positive cholangiocarcinomas showed a bile duct type of cholangiocarcinoma morphology (Fig. 1b) , while the cholangiolar type showed no positive staining (Fig.  1d ). Positive staining with MUC6 was seen in the reactive ductules surrounding the tumor but not in the bile ducts away from the tumor.
MUC6 Is a Unique Biomarker for Bile Duct Type of Intrahepatic Cholangiocarcinoma
Conclusions:
Our results indicate that MUC6 is a unique biomarker for bile duct adenomas and bile duct type of intrahepatic cholangiocarcinoma that distinguishes it from the cholangiolar type of cholangiocarcinoma. Given the morphologic overlap of the bile duct type of cholangiocarcinoma with bile duct adenoma, further investigation into the subclassifying of intrahepatic cholangiocarcinomas is warranted with regards to bile duct adenoma-carcinoma sequence, prognostic information and clinical behavior.
The Incidence of Steatosis and Steatohepatitis in Intrahepatic Cholangiocarcinoma and Extrahepatic Cholangiocarcinoma
George Eng, Lawrence Zukerberg, Vikram Deshpande. MGH, Boston, MA. Background: With the epidemic of obesity in the United States, there is increased incidence of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). Interestingly, incidence of intrahepatic cholangiocarcinoma (ICC) has also increased, raising the intriguing possibility of an association between the two. There have been variable reports of the concomitant prevalence of NASH with ICC. We propose using the incidence of a separate, yet anatomically similar malignant neoplasm, extrahepatic cholangiocarcinoma (ECC), to potentially compare the relative incidence of NASH with ICC. Design: We investigated 73 ICCs and 30 ECCs with associated histologically assessable liver tissue. Each cases was graded for steatosis, on a four tier scale: absent, mild, moderate and severe. Furthermore the presence of steatohepatitis and the grade of fibrosis was also determined. Standard Chi Squared analysis was used to compare the relative incidence of steatosis, steatohepatitis and fibrosis between the groups, ICC and ECC. Results: Steatosis between ICC and ECC was similar, with the presence of any steatosis being 36% (26/73) in the ICC group, and 30% (9/30) in the ECC group. The breakdown of steatosis severity for the ICC group was: absent 64% (47/73), mild 25% (18/73), moderate 11% (8/73) and severe 0% (0/73). The ECC group had a similar distribution of steatosis: absent 70% (20/30), mild 23% (7/30), moderate 7% (2/30) and severe 0% (0/30). Chi Squared analysis demonstrated no significant difference between the presence of steatosis in the ICC group or the ECC group, with a p value = 0.29. The prevalence of steatohepatitis was also similar between the two groups, with no steatohepatitis found in 93% (68/73) in ICC and 93% (28/30) in ECC cases. The Chi squared analysis had a p value = 0.95. Furthermore, the fibrosis was very similar between ICC and ECC, with 89% of ICC cases having none, similar to 92% of ECC cases. There was a slightly increased amount of cirrhosis identified in the ICC group compared to the ECC group, 8% (5/63) vs 0% (0/23), however there was a non-NASH etiology for all but one of the ICC associated cirrhosis cases: hemochromatosis, hepatitis B infection, hepatitis C infection, and alcohol abuse. Conclusions: These results show overall similar incidence of NASH occurring with ICC in our hospital's history of resectable ICC's when compared to recent studies. However, this incidence is very similar to the incidence of NASH in an anatomically similar, though potentially etiologically different malignancy, ECC. Mark Ettel, Gabriel Acosta-Gonzalez, Ogechukwu Eze, Shweta Gera, Cristina H Hajdu, James S Park, Samuel Sigal, Ruliang Results: BSEP was expressed in 91% of HCCs, and MDR3 was in 83%. Although their sensitivities were slightly lower than those of arginase-1 (96%) and HepPar-1 (93%), the two transporters appeared to be more specific for HCCs. Arginase-1 and HepPar-1 were expressed in ICCs (9% and 6%) and hepatoid carcinomas (22% and 44%, respectively), while BSEP and MDR3 were entirely negative in those neoplasms except for one case of BSEP-positive hepatoid carcinoma of the esophagus. The highly specific expressions of BSEP and MDR3 in hepatocytes were recapitulated in additional examinations on CHCs, where expressions of the transporters were restricted to morphologically hepatocellular areas. In contrast, arginase-1 and HepPar-1 were variably positive in areas of biliary or indeterminate differentiation as well. In the biopsy series, the diagnosis of HCC was retrospectively suggested in two cases, which were found to be positive for both BSEP and MDR3. Conclusions: Given highly specific expressions of BSEP and MDR3 in HCCs, immunohistochemistry for these transporters will be useful for not only determining hepatocellular differentiation in primary liver cancers but also discriminating HCCs from hepatoid carcinomas. Design: We optimized a novel pan-genotypic chromogenic in situ hybridization (ISH) assay for HEV RNA using RNAscope technology and validated the assay using HEV PCR-confirmed porcine and human controls. Next, we tested 7 liver biopsies from a single patient with unexplained allograft hepatitis over 4 years, clinically suspicious for HEV (positive HEV IgG). Then, we extended testing to 101 formalin fixed paraffin embedded tissue specimens from 85 patients with native livers (n=54) and allograft livers (n=47). The native livers had unexplained massive necrosis (n=23), chronic viral hepatitis B/C (n=9), autoimmune hepatitis (n=7), chronic biliary disease (n=4), presumed drug induced injury (n=6), hepatitis A (n=2), fatty liver disease (n=1) and the allografts had chronic rejection (n=17), chronic viral hepatitis (n=9), vascular disease (n=7), chronic biliary disease (n=4) unexplained allograft dysfunction (n=5), and protocol biopsies (n=4). Results: The novel ISH assay was positive in each of 7 consecutive biopsies from the patient with unexplained hepatitis. These biopsies showed non-specific mild portal and lobular inflammation without fibrosis. Ribavirin therapy in this patient led to rapid normalization of aminotransferases. Confirmatory HEV PCR on 6 of 6 biopsies for this patient was positive for HEV RNA. HEV ISH testing of the next 101 cases revealed a HEV positive rate of 2% (n=2); both patients had PSC and presented with unexplained allograft failure leading to re-transplantation after 4 and 6 weeks respectively because of graft dysfunction. One of the explants after re-transplantation showed diffuse non-necrotizing granulomata and the other marked cholestasis with mild portal and lobular inflammation. Conclusions: HEV ISH can be a useful tool for the diagnosis of HEV infection.
Frequency and Pathological Characteristics of Drug-Induced Liver Injury in a Tertiary Medical Center
PRKACA Fluorescent In Situ Hybridization Reveals Novel Findings in Fibrolamellar Carcinoma
Histologically confirmed cases of HEV affected patients after liver transplantation, displayed varied non-specific histologic features and contributed to allograft loss. , characterized by mucin production and diffuse immunoreactivity to S-100P arose less frequently from chronic liver diseases (26.2% vs. 48.2%, P = 0.027). Type 1 ICC displayed a higher level of serum CEA and CA 19-9 (P < 0.001) than type 2 ICC, which generally showed little mucin production or immunoreactivity to N-cadherin and/or NCAM. Type 1 ICC was characterized by higher frequencies of periductal spreading on macroscopic appearance, the presence of a poorly differentiated component, intraductal growth, cellular fibrosis, hepatic hilar involvement and perineural invasion (P < 0.001). Type 2 ICC more frequently displayed multifocal scar-like fibrosis (P < 0.001). Type 1 ICC was associated with a significantly worse recurrence-free and overall survival than type 2 ICC (P < 0.001). Genetically, KRAS mutation was more frequent in type 1 ICC (29.4% vs. 2.0%, P < 0.001), whereas IDH1/2 mutation was restricted to type 2 ICC (0.0% vs. 39.6%, P < 0.001). FGFR2 translocation was noted in only 6 of 95 cases examined, 5 of which were from type 2 ICC. Multivariate analysis revealed that the presence of a poorly differentiated component and intrahepatic metastasis were independent prognostic factors of recurrence-free and overall survival.
Conclusions:
The two histologic subsets defined here displayed distinct clinicopathologic and genetic characteristics, supporting the rationale for classification and indicating its importance both clinically and pathologically. 
Features of AH can only be classified with a poor-to-moderate level of interobserver agreement. Even though AHHS was reported to be useful in predicting short-term outcome in patients with AH, a significant interobserver variability among liver pathologists as revealed by the current study can limit its usefulness in everyday clinical practice. Bela Horvath, Hao Xie, John Guirguis, Daniela Allende, Michael Cruise, Deepa Patil, Robert O'Shea, John Rivas, Reyna Yordanka, Xiuli Liu. Cleveland Clinic, Cleveland, OH; Yale University, New Haven, CT. Background: Long standing congestive heart failure can induce a constellation of histopathology changes in the liver that ranges from mild sinusoidal dilation to advanced fibrosis. Liver biopsies might be performed to assess the peri-operative risk of these patients or to determine the need of synchronous liver transplant. We aimed to assess interobserver variability in recognizing these histologic features in patients undergoing evaluation for heart transplantation. Design: Hematoxylin-eosin and trichrome stained slides from 36 cases were reviewed by 4 gastrointestinal pathologists. Histologic features of congestive hepatopathy (CH) were reviewed, including evaluation of the overall fibrosis (stage) using a recently developed congestive hepatic fibrosis score (CHFS, Dai D-F et al. Mod Pathol. 2014; 27:1552-8) . Interobserver agreement analysis to determine the Fleiss' kappa coefficient (K) was performed.
Reproducibility of Evaluation of Liver Biopsies from Patients with Congestive Heart Failure
Results: Sinusoidal dilation, centrilobular hepatocyte atrophy, fibrosis and hemorrhage were the most common findings in this cohort. A fair-to-good level of interobserver agreement was reached among 4 reviewers on histopathological features ( ). An average of 770 (range 509-1288) cells per case were assessed. The overall number of mitoses in FLCs was remarkably low, with 7/12 cases showing no identifiable mitotic figures in the examined fields. The remaining 5 cases showed an average of 3.3 (range 2-9) mitoses per 1000 tumor cells and an average of 3.4 (range 1-10) mitoses per cm 2 of tumor tissue. Mitotic activity (>1/1000 tumor cells or cm 2 ) was predictive of significantly increased mortality (P=0.006) and decreased disease-free survival (P=0.04) on Kaplan-Meier analysis, was associated with stage>II at presentation (P=0.008), and showed a trend towards increased risk of distant metastasis (P=0.06). All long-term (>2 years) diseasefree survivors (n=3) had undetectable mitotic activity by the above-described method.
Conclusions:
The proliferative rate is an important prognostic indicator in the fibrolamellar variant of hepatocellular carcinoma and identification of even a small proportion of mitotically active tumor cells may be clinically significant. Background: In situ hybridization (ISH) for albumin is known to be a sensitive and specific test of primary liver tumors. Previous use has been limited by lack of a simple commercially available protocol. A recently released albumin ISH platform has been studied in adult primary liver tumors (hepatocellular carcinoma, intrahepatic cholangiocarcinoma) and demonstrated high sensitivity for these tumors, while non-liver primary tumors did not react. Pediatric liver tumors have not been previously tested. Two pediatric liver malignancies which can be challenging for histopathologists include hepatoblastoma (HPB) and fibrolamellar hepatocellular carcinoma (FL-HCC). HPB may be challenging due to varied morphology (fetal and embryonal patterns) while FL-HCC often resembles adenocarcinoma. The aim of this study is to determine if ISH for albumin is a viable option in the pathologic work-up of these childhood malignancies. A secondary aim is to compare albumin ISH to common immunohistochemical markers, HepPar1 (HEPA) and Arginase-1 (ARG). Design: Tissue microarrays (TMA) including 27 HPB and 10 FL-HCC were constructed. We evaluated a commercially available RNA ISH method using branched DNA technology to detect albumin (Affymetrix, Santa Clara, CA). Immunohistochemistry for HEPA (DAKO, Carpinteria, CA) and ARG(Sigma-Aldrich, St. Louis, MO) was carried out in the usual fashion. Results: 27 of 27 HPB had appreciable albumin RNA by ISH. These included 15 with fetal pattern, 8 embryonal pattern and 4 mixed (embryonal and fetal) patterns. One mixed pattern showed reactivity only in the fetal component (3/4 stained both components). 23/27 cases showed diffuse positivity whereas 4/27 were focal. All 10 FL-HCC were diffusely positive. Sensitivity was 100% for HPB and FL-HCC. The number of signals in the positive cells was generally very high and easily appreciated. ARG also had 100% sensitivity for HPB (26 of 26 cases) and FL-HCC (9 of 9). HEPA stained only 23 of 27 HPB (85% sensitivity) and 7 of 9 FL-HCC (78% sensitivity). Conclusions: Albumin RNA ISH is a useful test to determine hepatocytic origin in the relatively rare pediatric liver malignancies HPB and FL-HCC. ARG was equally sensitive and easy to interpret. HEPA was inferior to both in HPB and FL-HCC.
Applying Criteria for Hepatocellular Neoplasm of Uncertain Malignant Potential Reclassifies >50% of Hepatocellular Adenomas
Brent Larson, Maha Guindi. Cedars-Sinai Medical Center, Los Angeles, CA. Background: It can be impossible to differentiate hepatocellular adenoma (HA) from hepatocellular carcinoma (HCC). Hepatocellular neoplasm of uncertain malignant potential (HUMP) is a proposed diagnostic term for these problematic lesions. Criteria include focal reticulin loss, focal atypia, β-catenin (BC) activation, age >50 or <15 years, male sex, and tumors in glycogen storage disease. This study sought to validate the criteria on previously diagnosed HAs. Design: 41 HAs resected from 1994 to 2013 from 31 patients were retrospectively reviewed. All were previously characterized morphologically and immunohistochemically with BC (Cell Marque, Rocklin, CA) and glutamine synthetase (GS, BioCare, Concord, CA). GS and/or nuclear BC positivity was considered BC activation. Available records were reviewed. Results: 24 (59%) tumors met ≥1 criterion for HUMP. 10 (24%) met ≥2 criteria. The table lists criteria for each HUMP. 18 (58%) patients had a HUMP. HUMPs were 0.3-17 cm (mean: 5.9 cm) and HAs were 0.2-8.5 cm (mean: 3.9 cm), a difference approaching significance (p=0.509). 4 HUMPs had patchy GS staining without nuclear BC staining. For 2, this was the only HUMP-defining criterion. Of 31 patients, 3 had separate concurrent HCCs, only 1 of whom had a HUMP. Conclusions: Arg is more sensitive and specific for CCHCC compared to metastatic clear cell tumors than Hepar. Most cases show nuclear and/or cytoplasmic Arg positivity, and nuclear staining is preserved even when the cytoplasm is overtaken by fat or clearing.
Overall, Arg appears to be superior to Hepar for distinguishing CCHCC from clear cell tumors metastatic to the liver. Conclusions: Increased external pressure alone was associated with increased hepatocyte expression of lamins, decreasing nuclear deformability to buttress against this force, & a spherical nuclear shape, the optimal physical form to buttress increased pressure. Interestingly, the minimal changes with cirrhosis may reflect altered fluid dynamics & pressure. We thus show the importance of the physics, independent from the composition, of the microenvironment on nuclear structure. Background: Multistep hepatocarcinogenesis progresses from dysplastic nodules to early hepatocellular carcinoma (eHCC) and to advanced HCC. The aim of this study was to investigate the detailed histopathological features of eHCC. Design: We investigated 66 small vaguely nodular lesions resected from 40 patients. The degree of cellular and structural atypia and stromal invasion were assessed. The immunohistochemical expression of HCC-related markers adenylate cyclase-associated protein 2 (CAP2), heat shock protein 70 (HSP70), Bmi-1, CD34, and h-caldesmon were evaluated. Results: Of the 66 nodules, 10 were diagnosed as low-grade dysplastic nodules (LGDN), 10 as high-grade dysplastic nodules (HGDN), and 46 as eHCC. Among the 46 eHCCs, 18 nodules (39.1%) showed marked stromal invasion and/or the presence of the scirrhous component and were subclassified as high-grade eHCC (HGeHCC). The remaining 28 eHCCs, which lacked these features, were subclassified as low-grade eHCC (LGeHCC) and were examined further. HGeHCC showed high levels of cellular and structural atypia and large tumor size. The immunohistochemical expression of CAP2 and the area of sinusoidal vascularization showed increases from LGDN to HGeHCC. The density of arterial tumor vessels was high in HGeHCC compared with other nodule types. Cluster analysis of these parameters subclassified 65 nodules into HGeHCC-dominant, LGeHCC and HGDN-dominant, and LGDN-dominant groups.
Mechanical Forces Directly Modulate Hepatocellular Expression & Distribution of Nuclear Lamina Proteins Lamin
TFE3 Immunohistochemistry Is Useful to Distinguish Epithelioid Hemangioendotheliomas from Angiosarcomas and Hemangiomas of the Liver
Conclusions:
These results indicate the increased malignant potential of HGeHCC and suggest that it is already a transitional stage to advanced HCC. We consider that our grading classification system may be valuable for considering treatment strategies for eHCCs around 2 cm in diameter. Design: With the approval of IRB, a total of 49 wedge resection specimens from 49 patients were selected for the study. 5 µm paraffin sections were immunostained with Anti-Ngb and Anti-Cytb antibodies. The expression of Ngb and Cytb was evaluated with H-score method for both staining intensity (0-3) and percentage of positive cells (0-3). The mean value of the H-score of Ngb and Cytb in hepatocellular carcinoma and adjacent cirrhotic liver tissue were analyzed by two-way analysis variance. Survival curve was calculated using the Kaplan-meier method. All results with a p value <0.05 were considered statistically significant. Results: Most were males (40, 80%), predominatly Caucasians (28, 57%), with preexisting cirrhosis with a mean age of 63 years (range, 28-76 years), size ranges [55% had multiple nodules (average 1.5 cm) and 45% had single nodules (average 3.6 cm), vascular invasion (5/46,11%) and distant metastasis (2/49, 4%). Positive Ngb and Cytb displayed cytoplasmic/ perinuclear staining in hepatocytes. Compared to the adjacent cirrhotic areas, HCC's areas showed significant lower expression of Ngb (H score for Ngb, 141±71 in cirrhosis vs 88 ±53 in HCC, p< 0.01) and Cytb independent of age, >5 cm of tumor size, pTNM staging, vascular invasion/metastasis. The median cancer free survival is 4 years and 7/48 (15%) patients died during the 60 months median clinical follow-up. The patients with lower expression of Ngb and Cytb had a shorter survival compared to the ones with higher expression. Conclusions: Ngb and Cytb expression is decreased in HCC. The decreased expression of Ngb and Cytb may predict poor prognosis independent of tumor size, advanced TNM stage, presence of vascular invasion and metastasis. Background: Microvascular invasion (mVI) is a major prognostic factor in hepatocellular carcinoma (HCC). We previously showed that a modified form of histone H4 (histone H4 acetylation on lysine 16, H4K16ac), was significantly overexpressed in HCC with mVI (HCC/mVI+) compared to HCC without mVI (HCC/mVI-) (Poté et al., HEPATOLOGY 2013) . H4K16 acetylation plays a major role in transcription activation, and it has been shown that hMOF (human Males absent On the First), the H4K16 acetyltransferase, was involved in many cancers. How hMOF and H4K16 acetylation contribute to liver carcinogenesis remains elusive. Since chromatin-modifying enzymes have recently gained paramount importance in cancer therapy, it is worthwhile to investigate the role of hMOF in vascular invasion and tumor progression in HCC. Design: We first assessed hMOF expression by immunohistochemistry (IHC) and RT-qPCR in 55 HCC surgical specimens (mVI+, n=29; mVI-, n=26). For IHC, a semi-quantitative score (0-300) was calculated (% of stained cells [0-100] x staining intensity [1 weak; 2 intermediate; 3 strong]), blinded to the clinicopathological data. We next assessed hMOF role in cell proliferation, migration and invasion in hepatoma cell line PLC/PRF/5 using siRNA. Finally, a microarray transcriptomic analysis was performed to globally determine genes specifically regulated by hMOF and H4K16 acetylation in PLC/PRF/5 cell line. Results: hMOF was significantly overexpressed at the protein level in HCC/mVI+ compared to HCC/mVI-(IHC median score 180 versus 70; p= 0.002). siRNA-mediated hMOF knockdown led to a significant H4K16ac overall decrease and cell proliferation inhibition. Transcriptomic analysis showed that hMOF downregulation was associated with repression of genes involved in cell proliferation, migration, invasion and angiogenesis, including AXL, CYR61, LGALS1, FRS2, S1PR3 and CEACAM1. Conclusions: In summary, our results underpin a critical role for hMOF and H4K16 acetylation in vascular invasion and tumor progression in HCC, via transcriptional activation of genes involved in these processes. Furthermore, these data pave the way for future in vivo validation and additional experiments would further confirm the role of these genes in liver carcinogenesis.
This study examines the correlation of pathologic features of the tumor with recurrence, with emphasis on tumor differentiation, a feature that can potentially be evaluated on pre-transplant biopsies. Design: Of the 1,060 liver transplants performed at our institution between 1997 and 2015, 167 had a pre-operative diagnosis of HCC. 143 (86%) cases fell within Milan criteria, and 17 (10%) within UCSF criteria. The pathologic features of the tumor in the explant were recorded, along with clinical and follow-up data, and correlated with HCC recurrence risk.
Results: The risk of recurrence was significantly higher in poorly differentiated HCC (23%), compared to moderately differentiated (12%) and well differentiated histology (4%) (p=0.02). Three or more masses on pre-transplant radiologic evaluation was also a significant risk factor for recurrence (31% recurrence rate, p=0.04). In explants with one or two masses on pre-operative imaging (12% and 5% recurrence rate, respectively), those with poor differentiation showed a significantly higher recurrence rate of 31% (p=0.003, see Background: Allografts from DCD donors are associated with a 15-50% incidence of IC. A possible cause is thrombi formation in peribiliary arteriolar plexi due to flow stasis. Surgeons at our institute have initiated a protocol to flush the hepatic artery with tissue plasminogen activator (tPA) during procurement to prevent thrombi formation, eliminate IC and reduce risk of bleeding in DCD recipients. We compared liver biopsies taken during the first week post-transplantation from DCD allografts that received a tPA flush with those from DCD allografts that did not receive a tPA flush during procurement. Design: DCD allograft recipients with and without tPA flush at procurement were identified and clinical data obtained from the transplant surgery database. H&E stained slides of biopsies performed during the first week of transplantation were retrieved from the pathology archives. Hepatocellular necrosis, biliary epithelial injury, peribiliary neutrophilic infiltrate and bile ductular proliferation were each graded from 0 to 3. Acute rejection was graded as indeterminate, mild, moderate or severe. Presence of arteriolar thrombi was recorded.
Results:
DCD with tPA (n=18) DCD without tPA ( follow-up: range; median 9 mths-4 yrs; 2.5 yrs 6 mths-11 yrs; 8 yrs *grades 0,1,2,3 respectively
Occlusive thrombus in hepatic arteriole (inset). Bile duct shows apoptosis (arrow) and overlapping nuclei (arrow head)
Conclusions: 1) Hepatic arteriolar thrombi are a likely cause of IC in DCD allografts. A liver biopsy samples smaller peripheral portal tracts, thus limiting the finding of thrombi which are thought to form mainly in peribiliary plexi of large perihilar ducts. This may explain why thrombi were seen only in 2 biopsies that had not received a tPA flush.
2) Hepatic arterial tPA flush virtually eliminates IC.
3) Incidence of rejection is lower in allografts that receive tPA flush. Background: Histological diagnosis of acute cellular rejection in liver allografts is based on Banff schema that includes portal inflammation; bile duct damage; and venous endotheliitis. Each component of Banff schema is scored on a scale of 0 -3 and the added scores are reported as the final rejection activity index (RAI). One of the limitations of this traditional pathological evaluation is the variation in portal number in each liver biopsy and the patchiness of portal changes. The relatively low circulation pressure and large surface area make sinusoidal endothelium a unique interface between the graft and the recipient's immune system. Design: In this study, we investigated the feasibility of using sinusoid endotheliitis (SE) as an early diagnostic marker for liver allograft rejection by comparing the histological features of 45 liver transplant (LT) biopsies with acute cell rejection (ACR) and 37 cases with no evidence of ACR. Results: SE was scored as 1, focal linear lifting up the endothelial cells by inflammatory cells with no obvious damage to adjacent hepatocytes; 2, focal disruption of endothelial lining with subendothelial cluster of inflammatory cells; 3, severe confluent endotheliitis with hepatocyte loss and fibrosis. The sensitivity and specificity of diagnosing ACR using SE were 84% and 57%, respectively. The Positive predictive value (PPV) was 0.70, whereas the negative predictive value (NPV) was 0.75. Among 16 patients without ACR at the time of diagnosing SE, 6 cases (37.5%) had subsequent ACR in repeat biopsy. Conclusions: Our data suggest that SE scoring was a sensitive and specific parameter for diagnosing early ACR as well as predicting the occurrence of ACR in appropriate clinical setting. Recently treatment of recurrent HCV has significantly improved with the development of direct-acting antivirals with high rates of sustained virologic response (SVR). Ledipasvir/sofosbuvir (LS) is the first once-daily oral combination therapy that does not require the coadministration of interferon (IFN) and/or ribavirin. This is significant as IFN-based therapy has been associated with increased rates of acute rejection (ACR). Although studies have shown LS to have superior SVR rates compared to historical controls in the non-transplant population, its outcome on liver transplant recipients has not been studied. In this study, we examine the incidence of ACR of liver transplant recipients treated with LS. Design: We performed retrospective chart reviews of liver transplant recipients from 1/2012 to 8/2015. They were classified into 4 groups by the post-transplant protease inhibitor: LS, simeprevir (S), telaprevir (T), none (N). We collected data on recipient variables: sex, age at transplant, date of transplant as well as whether they received IFN therapy. ACR data included incidence, interval until first episode, severity, and number of episodes. Statistical analysis using Fisher's exact test was performed.
Primary and Secondary Hepatic Presentation of Hodgkin
Results: Out of 139 transplant recipients, 32 received LS, 13 received S, 5 received T, and 89 N. The T group received significantly more IFN therapy (80%) than other cohorts (N 2.2%, LS 9.3%, S 23%). The incidence of ACR did not differ significantly among the treatment groups: N (24%), S (46%), LS (50%), and T (60%), nor did the severity of ACR episodes by average Banff score (N 5±0.91, S 6±0.82, LS 8±0.82, and T 5±0.91). The N and LS groups both averaged 1 episode of ACR, which differed significantly from the S and T groups (mean = 2 episodes, p <0.05) . The S group had significantly longer time free from ACR from the N and T groups; the LS group did not show a significant difference from other groups. Conclusions: Treatment of recurrent HCV with LS after liver transplantation has a similar risk and severity of acute rejection as other protease inhibitors, and may result in fewer episodes of ACR. The decreased episodes of acute rejection may be partially due to the agent's allowance of IFN-free therapy. The tumors with CC were intrahepatic in 29, at the hilum in one and in the gallblader in one. Post-transplant, recurrence occurred in 7(23%) (1-26 mo., median 3 mo.), this group had significantly worse survival than patients without recurrence (Kaplan-Meier (p<.001).
1 large cell neuroendocrine carcinoma [LCNEC] now considered prostatic carcinoma, another LCNEC re-interpreted as WDNET); 1 poorly differentiated carcinoma (now LCNEC); and 1 spindle cell tumor (leiomyosarcoma instead of sarcomatoid carcinoma).
Conclusions:
The cytopathologist and gastrointestinal pathologist are highly concordant in the interpretation of liver mass core biopsy, especially for neoplastic cases. Consultation between them will likely improve diagnostic accuracy in certain non-neoplastic biopsies. Background: GATA4 is a transcription factor playing roles in development of varying organs, especially cardiac development. Recently, aberrant GATA4 expression has been studied in tumors of gastrointestinal tract, breast, lung, ovary, pancreas, and brain. However, the role of GATA4 in human cancers is still controversial. For example, down-regulation of GATA4 expression by promoter hypermethylation has been found, and acts as a tumor suppressor in colorectal and gastric cancers. On the other hand, high GATA4 expression has been revealed as a poor prognostic factor in ovarian granulosa cell tumors and breast cancers. We examined the expression of GATA4 protein in hepatocellular carcinoma and correlated with the clinicopathological parameters. Design: Tissue microarrays were constructed using 213 surgically resected primary hepatocellular carcinomas. Immunohistochemical stain was performed and interpreted by immunoreactive score, which was calculated by multiplying staining intensity score (0-3) and proportion score (0-4). Histology of the tumors and medical records of the patients were reviewed and statistical analyses were performed to investigate the relationship between clinicopathologic factors and GATA4 expression.
GATA4 Expression Is a Prognostic Factor of Recurrence in Hepatocellular Carcinoma
Results:
The tumors with 4 or more immunoreactive score were regarded as 'positive', accounting for 48.8%. GATA4-positive tumors were significantly associated with higher pathologic stage (p<0.001, chi-square test), higher histologic grade (p<0.001, chi-square test), more frequent small vessel invasion (p<0.001, chi-square test), and tumor recurrence (p = 0.039, log-rank test). Furthermore, mean Ki-67 proliferative index of GATA4-positive tumors was significantly higher than GATA4-negative tumors (11.60% vs. 3.56%, p<0.001, t-test).
Conclusions: While silence of GATA4 expression due to epigenetic mechanism was suggested to have roles in some human cancers, this result is implying GATA4 has an oncogenic role and may confer aggressive biology and poor prognosis to the hepatocellular carcinoma. Background: Steatohepatitic hepatocellular carcinoma (SH-HCC) is a recently described variant of hepatocellular carcinoma (HCC), with distinct morphological features, genetic traits, and is suggested to be associated with metabolic syndrome. We aimed to search the clinical and pathological importance of steatohepatitic and steatotic features in our HCC series. Design: Histopathological features, clinical and biochemical data of 151 HCC cases treated in our institution were retrospectively analyzed. The diagnosis of SH-HCC was made, if the tumor was bearing at least three of the "steatohepatitic" features in more than 50% of the tumor, and in multiple tumors if at least one nodule met the above criteria. Cases were reclassified as SH-HCC, SH-HCC<50%, steatotic HCC (SHCC) and classical HCC groups. Results: The mean age in this series was 54 (range, 11-75). There were 127 male (84%) and 24 (16%) female patients. Etiology was viral in 100 (70.1%), steatohepatitic in 9 (5.9%), viral+steatohepatitic in 16 (10.6%) and unknown in 18 (11.9%) cases. There were 13 SH-HCC (8.6%), 22 SH-HCC<50% (14.6%), 13 SHCC (8.6%), and 103 classical HCC (68.2%) cases. There were no significant differences between the four groups with respect to demographic and biochemical tests, AFP levels, mean BMI, presence of diabetes mellitus and hiper/dyslipidemia. Tumor size, uni-or multifocality, differentiation, nuclear grade, background liver features, presence of viral etiology, presence of microvascular invasion and survival did not show any difference between the groups neither. SH-HCC group had significantly high non-viral etiology (53.8%) (p=0,037) and frequent presence of NASH, but the latter was not significant. SH-HCC<50% group was characterized by significantly higher alcohol etiology (p=0,037), high (77.3%) but insignificant HBV etiology. Steatotic HCC had the highest HCV etiology (30.8%) without any statistical significance. Baring ant amount of SH-HCC did not confer any significant difference from classical HCC with respect to clinicopathological features. When HCCs with and without steatosis (regardless of the presence of SH-HCC component) were compared, cases with steatosis had high BMI (>25 kg/m2) (p=0.037). Conclusions: Steatosis can exist in HCC in association with viral etiology and/or high BMI but this has no clinical significance. Steatohepatitic features in HCC can also be seen in the presence of viral etiology. When strict criteria used SH-HCC is a variant associated mostly with non-viral etiology but without any prognostic significance.
Associations of Tumor Response to Neoadjuvant TACE Following Liver Transplantation
Yang Zhang, William S Twaddell. University of Maryland, Baltimore, MD. Background: Although the mainstay of therapy for hepatocellular carcinoma (HCC) is surgical resection, the majority of patients are not eligible because of tumor extent or underlying liver dysfunction. As a result, liver transplantation for patients with HCC has increased in recent years. Transarterial chemoembolization (TACE) therapy has been commonly used as a bridging therapy for unresectable tumors prior to transplant. However, response to TACE is extremely variable from patient to patient. Design: Pathology cases of HCC from 2011-2015 were reviewed for those treated with TACE prior to transplantation. 55 cases were identified with full information regarding tumor response to TACE. These were additionally reviewed for patient age, sex, diagnosis, presence of lymphovascular invasion, and differentiation, size, and number of tumors. Degree of tumor response was divided into 3 groups: complete response (CR), no viable tumor; high response (HR), > 50% tumor necrosis; and low response (LR), ≤ 50% tumor necrosis. Results: The 3 groups were demographically similar (table 1) . The presence of multiple tumors was strongly associated with incomplete response to TACE (p<0.05). Tumor size was not associated with tumor response group (p>0.05). Degree of differentiation could not be assessed in the CR group; however, there was no significant difference in the proportion of poorly differentiated tumors between the LR and HR groups. The presence of microscopic lymphovascular invasion was not associated with tumor response, although there was a trend towards significance in the LR versus HR groups (p = 0.08). As with degree of differentiation, the presence of lymphovascular invasion could not be assessed in the CR group. 
Results:
The most frequent histologic findings were spotty non-zonal hepatocyte necrosis (88%), mixed portal inflammation (85%), pericentral hepatocytes injury/ necrosis (80%), bile duct injury (65%), ductular proliferation (46%), and cholestasis (38%). Less common were portal vein endotheliitis (31%), sinusoidal neutrophils (31%), portal edema (27%), and ductopenia (23%). The degree of spotty hepatocyte necrosis was the only histologic change significantly associated with higher levels of DSA (p<0.05). Positive C4d IHC staining was seen in only 6 biopsies (26%), but was observed in all patients at one point. Three patients had ACR preceding elevation of DSA, and severity of ACR also correlated with DSA levels (p<0.05).
Conclusions:
Our results suggest that histopathology of acute liver AMR is variable and overlaps significantly with those seen in other post-transplant complications. Hepatocellular necrosis is the most frequent finding and the only one that correlates significantly with DSA levels. Histopathologic diagnosis of acute AMR is particularly challenging when co-existing with ACR due to overlapping features. ACR severity also correlates significantly with high DSA levels, which suggests the simultaneous occurrence of AMR and ACR, as one immunologic event might trigger another. C4d IHC stain is not a reliable diagnostic modality, given low sensitivity and prior reports of low specificity. Multicenter studies and establishing diagnostic criteria are important next steps for improvement of AMR diagnosis. 
